T here is much evidence that intrapartum transmission occurs through mucosal exposure of the fetus to HIVcontaining cervicovaginal secretions (CVSs). [1] [2] [3] In the absence of antiretroviral intervention, intrapartum transmission was found to be associated with HIV-1 DNA in the oropharyngeal secretions (OPS) of children. 4 Two studies using zidovudine long-term treatment analyzed a possible relationship between HIV-1 in OPSs and intrapartum transmission. 5, 6 We recently reported on the high concentrations of nevirapine (NVP) detected in CVSs and OPSs of babies after administration of a single dose of NVP to the mother. 7 Here, we analyze the extent of intrapartum transmission after mucosal exposure of the fetus to HIV-1 in the context of single-dose NVP administration.
METHODS
All HIV-positive pregnant women participating in the German Agency for Technical Cooperation (GTZ)-supported prevention of mother-to-child transmission of HIV (PMTCT) program in western Uganda who delivered at Fort Portal District Hospital (Kabarole District, Uganda) between September 2003 and 2004 were eligible for the study. All women and their babies participating in the PMTCT program received single-dose NVP prophylaxis according to the national policy at that time. Women had to give informed consent before enrollment.
Blood samples from mothers were collected at delivery but after the intake of the NVP tablet. Blood samples from children were taken at delivery and at weeks 1, 2, and 6 after birth; umbilical cord blood was used at birth. Specimens were centrifuged, and the plasma was frozen at 280°C. An OPS was collected from newborns within 15 minutes after birth, which corresponded to 0.3 to 25 hours after maternal intake of NVP but before the NVP syrup was given to the newborn. A GH8 mucus extractor specifically designed for the collection of mucosal secretions from babies was used for collection of OPSs (Medicoplast, Illingen, Germany); collection volume ranged from 0.2 to 1.5 mL. Specimens were divided into aliquots for determination of HIV-1 and NVP concentrations and stored at 280°C. CVSs were collected between 0.17 and 24 hours after maternal NVP intake; 1 Sno Strip each (filter paper strip; Chauvin Pharmaceuticals, Kingston, United Kingdom) was used to collect primarily cell-free virions from the cervicovaginal fluid. 8 Sno Strips were transferred into a cryotube and stored at 280°C.
HIV-1 determination in plasma, CVSs, and OPSs was performed by reverse transcriptase polymerase chain reaction (PCR) using the Amplicor HIV-1 monitor assay (version 1.5; Roche Diagnostics; Mannheim, Germany) according to the manufacturer's recommendations. 9 In 2 cases, maternal blood samples taken at delivery were analyzed by the ultrasensitive Amplicor HIV-1 monitor test, with a detection limit of 50 copies/mL. For RNA extraction from CVSs, the Sno Strips were incubated in 400 mL of guanidine thiocyanate-containing lysis reagent for 15 minutes. The samples were vigorously vortexed for 15 seconds twice, and the Sno Strips were removed. Separation of OPSs in cell pellets and supernatant was not performed; thus, cell-free and cell-associated HIV-1 may have been amplified. The lower detection limit for HIV-1 was 500 copies/mL for plasma and 100 copies/mL for OPSs and CVSs. To define the lower limit of detection, HIV-negative OPSs and CVSs were previously spiked with different quantities of HIV-1 RNA.
Concentrations of NVP in OPSs were determined by validated liquid chromatography-tandem mass spectrometry (LC-MS), as previously described for plasma. 10 The lower limit of detection was 15 ng/mL.
In utero transmission was defined as a positive HIV-1 RNA PCR result at delivery (,1 hour). Intrapartum transmission was defined as a positive HIV-1 RNA PCR result at week 1 or at week 2 preceded by a negative PCR result at delivery or at week 1, respectively. Postpartum transmission was assumed if the 6-week specimen showed a positive PCR result, whereas previous specimens, including the 2-week specimen, were negative. This definition was chosen because HIV-1 DNA PCR was shown to reach a sensitivity of 93% at week 2 after birth 11 and because HIV-1 RNA PCR as used in our study was demonstrated to be equally or even more sensitive than HIV-1 DNA PCR. 12 Statistical analysis was performed using SPSS version 12.0 (Chicago, IL). Medians and interquartile ranges (IQRs) are indicated for HIV-1 and NVP concentrations. Correlations between quantitative variables were determined using the Spearman rank correlation coefficient. HIV-1 and NVP concentrations lower than the limit of detection were considered to be 0 copies/mL and 0 ng/mL, respectively. The study was approved by the National Council of Science and Technology of Uganda as part of the evaluation of the PMTCT program.
RESULTS
The median age of the 80 women was 26 years (IQR: 21-30 years); 80.5% had a primary education or had not attended school. The median body weight of the 80 women was 60 kg (IQR: 55-67 kg), and the median CD4 count was 476 cells/mL (IQR: 222-631 cells/mL). The median interval between maternal intake of 200 mg of NVP and delivery was 5.6 hours (IQR: 3.02-9.75 hours, maximum of 25 hours). All but 1 woman had taken the NVP tablet at least 1 hour before delivery, and none had received further antiretroviral treatment. All newborns received 2 mg/kg of NVP syrup under observation within 3 days after delivery (median = 0.9 hours after birth, IQR: 0.5-7.0 hours). The cesarean delivery rate was 11.7%, with all being emergency cesarean sections. Eighty mothers gave birth to 82 babies. The newborns' median birth weight was 3025 g (IQR: 2798-3500 g). A total of 85.9% of the mothers breast-fed the babies exclusively during the period under investigation, and 14.1% used replacement feeding.
Seventy-three of 81 OPSs were analyzable, whereas 8 were nonfluid agglutinated conglomerates that were not quantifiable. There was a significant correlation between the NVP concentration achieved in OPSs and the time interval since maternal NVP intake (r = 0.35, P = 0.003; Fig. 1 ). Seventy-one (97%) of 73 babies had detectable NVP in their OPS, with the median concentration being 592 ng/mL (IQR: 197-1070 ng/mL). In the 2 cases without a measurable NVP concentration, the mothers had taken NVP 0.3 and 1.8 hours before the specimen was taken. In 86% of OPSs, NVP concentrations were 10 times the median inhibitory concentration (IC 50 ) for NVP (.100 ng/mL).
HIV-1 levels were measured in 79 OPSs, of which 9 showed PCR inhibition. Fifty-seven (81%) OPSs were HIV-1 negative, and 13 (19%) were HIV-1 positive. The median HIV-1 level in the 13 HIV-1-positive OPSs was 600 copies/mL (IQR: 259-1811 copies/mL).
There was no correlation between HIV-1 and NVP concentrations of the OPSs (r = 0.12, P = 0.35), nor did parameters correlate when only OPSs with detectable HIV-1 were analyzed.
The median HIV-1 RNA load in the CVSs was 18,633 copies/mL (IQR: 5687-42,705 copies/mL, n = 60). For 44 mother-child pairs, HIV-1 determinations were available for OPSs and CVSs. HIV-1 levels of OPSs and CVSs of the mother-child pairs correlated (r = 0.33, P = 0.027). All babies of mothers with an undetectable HIV-1 RNA level in the CVS (n = 15) were negative for HIV-1 in the OPS. All mothers of babies with a detectable HIV-1 in the OPS (n = 7) had detectable HIV-1 RNA in the CVS. In 50% (n = 22) of the mother-child pairs, the mother had a positive HIV-1 RNA PCR result in the CVS, whereas HIV-1 in the OPS of the baby was not detectable. The median ratio of the detectable OPS-to-CVS viral load was 1:18. The median HIV-1 RNA level in maternal plasma was 4930 copies/mL (IQR: 2306-64,826 copies/mL). The median interval between NVP intake and sample collection of maternal blood was 5.6 hours (IQR: 3.3-10.5 hours). For 58 mother-child pairs, HIV-1 levels in the OPSs and in maternal plasma at delivery were available. There was no correlation between these 2 parameters (r = 0.08, P = 0.55), nor did parameters correlate when only OPSs with detectable HIV-1 were analyzed. Two babies had detectable HIV-1 in their OPS, whereas HIV-1 RNA was not detectable in their mothers' plasma.
Details of the 13 babies with detectable HIV-1 in their OPSs are shown in Table 1 . The HIV status was evaluable for 12 of these infants at week 6. Eleven (92%) of 12 babies with HIV-1 positive OPSs at delivery had no detectable HIV in their plasma at week 6. One child was infected post-partum; this child had been exclusively breast-fed. The HIV status of 47 of 57 infants without detectable HIV-1 in the OPSs was assessed at week 6 (10 infants were lost to follow-up). Six were HIVpositive, and 41 were HIV-negative. Three of the 6 had been infected in utero; 1 was infected intrapartum; and for 2 infants, the time of infection remained unknown (missing sample at delivery). Altogether, 1 (8%) of 12 children with detectable HIV-1 in their OPS and 6 (13%) of 47 infants without detectable HIV-1 in their OPS were infected with HIV at week 6. None of the children with detectable HIV-1 in their OPS had become infected intrapartum.
DISCUSSION
The mucosal hypothesis for intrapartum transmission is supported by a higher risk of transmission with higher levels of cell-free and cell-associated HIV-1 in CVSs independent from the maternal plasma viral load. [1] [2] [3] The presence of HIV-1 in OPSs and its role in HIV transmission have thus far received little attention. In the absence of antiretroviral intervention, 46% (11 of 24) of babies with detectable HIV DNA in their OPS at birth were found to be infected with HIV-1 at week 6 (in utero-infected babies excluded). 4 The HIV status was assessed at week 6 only; therefore, some of these infections could have been acquired through early breast-feeding. In our study, after single-dose NVP was administered to the mother and the baby, none of the babies with HIV-1 in their oral cavity became infected with HIV intrapartum. Similarly, after having received long-term zidovudine-based antiretroviral treatment, only 1 of 28 babies and none of 9 babies with detectable HIV-1 RNA in oropharyngeal and gastric aspirations became infected intrapartum. 5, 6 According to our definition, intrapartum transmission was not considered if the child's plasma sample was HIV-negative at week 2. Although unlikely, misclassification of the 1 baby who was defined as being infected postpartum (positive PCR result at week 6 and negative PCR result at week 2) cannot completely be excluded.
In our study, all OPSs of children of mothers with undetectable HIV-1 RNA in their CVS were HIV-negative and all CVSs of mothers of children with detectable HIV-1 in their OPS were HIV-positive. Furthermore, we found a significant correlation between HIV-1 levels in OPSs and CVSs and no significant correlation between HIV-1 levels in OPSs and maternal plasma. Two babies had detectable HIV-1 in their OPS, although HIV-1 RNA was not detectable in their mothers' plasma. We thus assume that the CVS of the mother is an important source of HIV in the baby's OPS. One baby with detectable HIV in the oral cavity (but with a negative HIV status at week 6) was delivered by emergency cesarean section. In this case, the source of HIV was probably different and could have been maternal blood or amniotic fluid.
One baby without detectable HIV-1 in its OPS became infected intrapartum. Other mechanisms of transmission must therefore be considered; for example, a nonmucosal route via maternal-fetal microtransfusion. 13 Early postnatal infection cannot be excluded either. This child's PCR result was positive 2 weeks after birth, and the mother had a high HIV-1 viral load in her breast milk (10 6 copies/mL, data not shown). 
